Guidance on Novel Influenza A/H1N1 in Solid Organ Transplant Recipients

Officially endorsed by the American Society of Transplantation (AST), The Transplantation Society (TTS) and the Canadian Society of Transplantation (CST)


  • This Document is provided for informational and general educational purposes only. Nothing contained in this Document is intended to be instructional for medical diagnosis or treatment. This Document should not be used in place of professional medical advice and is not intended to be a substitute for consultation with or treatment by a medical professional. This Document is an educational tool designed only to enhance and support the treatment and education process initiated by your physician, nurse or pharmacist. This Document should not be substituted for specific medical advice or instruction by a physician, nurse or pharmacist.

Corresponding author: Deepali Kumar,


Novel influenza A/H1N1 virus has caused significant illness worldwide. In response to this global crisis, the American Society of Transplantation (AST) Infectious Diseases Community of Practice and the Transplant Infectious Diseases section of The Transplantation Society (TTS) developed a guidance document for novel H1N1. In this paper, we discuss current guidance for H1N1 as it relates to solid organ transplantation. We include discussion around clinical presentation, diagnosis, therapy and prevention specifically addressing areas such as chemoprophylaxis, immunization and donor-derived infection. Although this document addresses conditions specific to novel H1N1, many principles could be applied to future pandemics. As new information emerges about novel H1N1, updates will be made to the electronic version of the document posted on the websites of the AST and TTS.